Clinically relevant drug interactions in anxiety disorders

Human Psychopharmacology

Volumn 27, Issue 3, 2012, Pages 239-253

  Muscatello, Maria Rosaria ^a   Spina, Edoardo ^a   Bandelow, Borwin ^b   Baldwin, David S ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

anxiety disorders; benzodiazepines; drug interactions; pregabalin; selective serotonin reuptake inhibitors; serotonin noradrenaline reuptake inhibitors

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; ANXIOLYTIC AGENT; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GLUCURONIC ACID; GLYCOPROTEIN P; LORAZEPAM; METOPROLOL; MOOD STABILIZER; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; PAROXETINE; PREGABALIN; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

ANXIETY DISORDER; COMORBIDITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DATABASES, BIBLIOGRAPHIC; DRUG INTERACTIONS; HUMANS;

EID: 84861182124     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2217     Document Type: Review

References (143)

1. Ahern TP, Pedersen L, Cronin-Fenton DP, et al,. 2009. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 18: 2562-2564.
2. Alderman J, Preskorn SH, Greenblatt DJ, et al,. 1997. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17: 284-291. (Pubitemid 27312427)
3. Amchin J, Zarycransky W, Taylor KP, et al,. 1999. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol 39: 297-309. (Pubitemid 29148553)
4. Andersen BB, Mikkelsen M, Vesterager A, et al,. 1991. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res 10: 201-204.
5. Avenoso A, Facciolà G, Scordo MG, et al,. 1998. No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia. Clin Drug Invest 16: 393-398. (Pubitemid 28526386)
6. Baldwin DS, Anderson IM, Nutt DJ, et al,. 2005. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19: 567-596. (Pubitemid 41578819)
7. Bandelow B,. 2008. The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectr 13 (9 Suppl 14): 37-46.
8. Bandelow B, Zohar J, Hollander E, et al,. 2008. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders. First revision. World J Biol Psychiatry 9: 248-312.
9. Becquemont L, Raguenau I, Le Bot MA, et al,. 1997. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 61: 619-627. (Pubitemid 27279923)
10. Bergstrom RF, Peyton AL, Lemberger L,. 1992. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 51: 239-248.
11. Bockbrader HN, Burger P, Knapp L,. 2011. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate and tiagabine. Epilepsia 52: 405-409.
12. Bondolfi G, Eap CB, Bertschy G, et al,. 2002. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychiatric patients. Pharmacopsychiatry 35: 50-56. (Pubitemid 34293233)
13. Bonnet P, Vandel S, Nezelof S, et al,. 1992. Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? Therapie 47: 165.
14. Borges S, Desta Z, Li L, et al,. 2006. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implications for optimization of breast cancer treatment. Clin Pharmacol Ther 80: 61-74. (Pubitemid 43946844)
15. Boyer EW, Shannon M,. 2005. The serotonin syndrome. New Engl J Med 352: 1112-1120.
16. Breitbart W,. 2011. Do antidepressant reduce the effectiveness of tamoxifen? Psychooncology 20: 1-4.
17. Brodie MJ, Wilson EA, Wesche DL, et al,. 2005. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 46: 1407-1413.
18. Cai WM, Chen B, Zhou Y, Zhang YD,. 1999. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. Clin Pharmacol Ther 66: 516-521.
19. Calvo G, Garcia-Gea C, Luque A, et al,. 2004. Lack of pharmacological interaction between paroxetine and alprazolam at steady state in healthy volunteers. J Clin Psychopharmacol 24: 268-276. (Pubitemid 38658034)
20. Carrier L,. 1999. Donepezil and paroxetine: possible drug interaction. J Am Geriatr Soc 47: 1037 (Pubitemid 29380504)
21. Carroll DG, Kelley KW,. 2009. Use of antidepressants for management of hot flashes. Pharmacotherapy 29: 1357-1374.
22. Castberg I, Skogvoll E, Spigset O,. 2007. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 68: 1540-1545. (Pubitemid 350073402)
23. Centorrino F, Baldessarini RJ, Frankenburg FR, et al,. 1996. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153: 820-823.
24. Centorrino F, Baldessarini RJ, Kando J, et al,. 1994. Serum concentrations of clozapine and its metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 151: 123-125. (Pubitemid 24020124)
25. Chappell J, He J, Knadler MP, et al,. 2009. Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady-state in healthy subjects. J Clin Pharmacol 49: 1456-1466.
26. Chubak J, Buist DS, Boudreau DM, et al,. 2008. Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat 112: 123-132.
27. Chung JY, Cho JY, Yu KS, et al,. 2008. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 83: 595-600.
28. Ciraulo DA, Shader RI, Greenblatt DJ, Creelman W,. 1995. Drug Interactions in Psychiatry, 2nd edn. Williams & Wilkins: Baltimore.
29. Cozza KL, Armstrong SC, Oesterheld JR,. 2003. Concise Guide to Drug interaction Principles for Medical Practice: Cytochrome P450s, UG7-s, P-Glycoproteins, 2nd edn. American Psychiatric Association: Washington, DC.
30. Dalton SO, Johansen C, Mellemkjaer L, et al,. 2003. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding. Arch Intern Med 163: 59-64. (Pubitemid 36091601)
31. Dalton SO, Sorensen HT, Johansen C,. 2006. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 20: 143-151. (Pubitemid 43261698)
32. De Abajo FJ, Garcia-Rodriguez LA,. 2008. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 65: 795-803. (Pubitemid 351957705)
33. De Abajo FJ, Montero D, Garcia-Rodriguez LA, Madurga M,. 2006. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Ther 98: 304-310.
34. De Abajo FJ, Rodriguez LAG, Montero D,. 1999. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Br Med J 319: 1106-1109. (Pubitemid 29494721)
35. de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L,. 2001. Interaction of olanzapine with fluvoxamine. Psychopharmacology 155: 219-220. (Pubitemid 32417833)
36. Dent LA, Orrock MW,. 1997. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 17: 170-172. (Pubitemid 27057132)
37. Desmerais JE, Looper KJ,. 2009. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 70: 1688-1697.
38. Desta Z, Ward BA, Soukhova NV, Flockhart DA,. 2004. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent role for CYP3A and CYP2D6. J Pharmacol Exp Ther 310: 1062-1075. (Pubitemid 39108928)
39. Devane CL, Markowitz JS, Hardesty SJ, et al,. 1997. Fluvoxamine-induced theophylline toxicity. Am J Psychiatry 154: 1317-1318.
40. Dezentjé VO, van Blijderveen NJ, Gelderblom H, et al,. 2010. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence of breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28: 2423-2429.
41. Drake WM, Gordon GD,. 1994. Heart block in a patient on propranolol and fluoxetine. Lancet 343: 425-426. (Pubitemid 24049581)
42. Duncan D, Sayal K, McConnell H, Taylor D,. 1998. Antidepressant interactions with warfarin. Int Clin Psychopharmacol 13: 87-94. (Pubitemid 28218520)
43. Englisch S, Esser A, Enning F, et al,. 2010. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol 30: 437-440.
44. European Medicines Agency. 2011. Pharmacovigilance Working Party (PhVWP) monthly report, issue 110. Annex 2: Citalopram-risk of QT interval prolongation. 27th October 2011.
45. Fabrazzo M, La Pia S, Monteleone P, et al,. 2000. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. J Clin Psychopharmacol 20: 708-710.
46. Fleishaker JC, Hulst LK,. 1994. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46: 35-39. (Pubitemid 24067586)
47. Frank C,. 2008. Recognition and treatment of serotonin syndrome. Can Fam Physician 54: 988-992.
48. Fritze J, Unsorg B, Lanczik M,. 1991. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 84: 583-584.
49. Furukori H, Otani K, Yasui N, et al,. 1998. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology 18: 364-369. (Pubitemid 28140661)
50. Gardner MJ, Baris BA, Wilner KD, et al,. 1997. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet 32 (Suppl. 1): 43-49. (Pubitemid 27107719)
51. Gillman PK,. 2006. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59: 1046-1051. (Pubitemid 43849654)
52. Gillman PK,. 2007. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151: 737-748. (Pubitemid 47075311)
53. Glueck CJ, Khalil Q, Winiarska M, Wang P,. 2006. Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio. JAMA 295: 1517-1518.
54. Goetz MP, Knox SK, Suman VJ, et al,. 2007. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101: 113-121. (Pubitemid 47555336)
55. Goryachkina K, Burbello A, Boldueva S, et al,. 2008. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 64: 275-282.
56. Graff DW, Williamson KM, Pieper JA, et al,. 2001. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Clin Pharmacol 41: 97-106.
57. Greenblatt DJ, von Moltke LL,. 2010. Clinical studies of drug-drug interactions: design and interpretation. In Enzyme- and Transporter-Based Drug-Drug Interactions, Pang KS, Rodrigues AD, Peter RM, (eds). Springer: New York; 625-649.
58. Greenblatt DJ, Preskorn SH, Cotreau MM, et al,. 1992. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 52: 479-486.
59. Grimsley SR, Jann MW, Carter JG, et al,. 1991. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 50: 10-15.
60. Gustansson A, Svensson M, Jacobi F, et al,. 2011. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21: 718-779.
61. Hartter S, Wetzel H, Hammes E, Hiemke C,. 1993. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology 110: 303-308.
62. Hassan PC, Sproule BA, Naranjo CA, Herrmann N,. 2000. Dose-response evaluation of the interaction between sertraline and alprazolam in vivo. J Clin Psychopharmacol 20: 150-158. (Pubitemid 30202356)
63. Hauta-Aho M, Tirkkonen T, Vahlberg T, Laine K,. 2009. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 41: 619-628.
64. Hemeryck A, Belpaire FM,. 2002. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 3: 13-37. (Pubitemid 34296308)
65. Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM,. 2000. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 67: 283-291. (Pubitemid 30176387)
66. Hendset M, Molden E, Enoksen TB, et al,. 2010. The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data. Ther Drug Monit 32: 787-790.
67. Hiemke C, Avi P, Jabarin M, et al,. 2002. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 22: 502-506.
68. Hiemke C, Weighmann H, Hartter S, et al,. 1994. Elevated serum levels of clozapine after addition of fluvoxamine. J Clin Psychopharmacol 14: 279-281. (Pubitemid 24254723)
69. Isbister GK, Buckley NA, Whyte IM,. 2007. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 187: 361-365.
70. Jalil P,. 1992. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry 55: 412-413.
71. Jerling M, Lindstrom L, Bondesson U, Bertilsson L,. 1994. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16: 368-374. (Pubitemid 24222520)
72. Jin Y, Desta Z, Stearns V, et al,. 2005. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97: 30-39.
73. Juurlink DN, Mamdani MM, Kopp A, et al,. 2005. A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin. Br J Clin Pharmacol 59: 102-107. (Pubitemid 40040102)
74. Kelly CM, Juurlink DN, Gomes T, et al,. 2010. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population-based cohort study. Br Med J 340, c693. DOI: 10.1136/bmj.c693.
75. Kurdyak PA, Juurlink DN, Kopp A, Herrmann N, Mamdani MM,. 2005. Antidepressants, warfarin, and risk of hemorrhage. J Clin Psychopharmacol 25: 561-564.
76. Lane R, Baldwin DS,. 1997. Selective serotonin reuptake inhibitor-induced serotonin syndrome: a review. J Clin Psychopharmacol 17: 208-221. (Pubitemid 27261777)
77. Lash TL, Cronin-Fenton DP, Ahern TP, et al,. 2010. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 49: 305-312.
78. Lash TL, Cronin-Fenton DP, Ahern TP, et al,. 2011. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst. DOI: 10.1093/jnci/djr010.
79. Lash TL, Pedersen L, Cronin-Fenton D, et al,. 2008. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 99: 616-621.
80. Lehmann D, Nelsen J, Ramanath V, et al,. 2004. Lack of attenuation of antitumor effect of tamoxifen by chronic CYP isoform inhibition. J Clin Pharmacol 44: 861-865. (Pubitemid 38971567)
81. Leibovitz A, Bilchinsky T, Gil I, Habot B,. 1998. Elevated serum digoxin level associated with coadministered fluoxetine. Arch Intern Med 158: 1152-1153. (Pubitemid 28242322)
82. Lemberger L, Rowe H, Bosomworth JC, et al,. 1988. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 43: 412-419.
83. Limke KK, Shelton AR, Elliott ES,. 2002. Fluvoxamine interaction with warfarin. Ann Pharmacother 36: 1890-1892. (Pubitemid 35429561)
84. Lin JH,. 2007. Transporter-mediated drug interactions. Clinical implications and in vitro assessment. Exp Opin Drug Metab Toxicol 3: 81-92. (Pubitemid 47307456)
85. Lin JH, Lu AYH,. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35: 361-390. (Pubitemid 28520008)
86. Livingston MG, Livingston HM,. 1996. Monoamine oxidase inhibitors: an update on drug interactions. Drug Saf 14: 219-227. (Pubitemid 26128811)
87. Loke YK, Trivedi AN, Singh S,. 2008. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 27: 31-40. (Pubitemid 350212624)
88. Loprinzi CL, Qin R, Balcueva EP, et al,. 2010. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 28: 641-647.
89. Lorenz RA, Jackson CW, Saitz M,. 2010. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy 30: 942-951.
90. Moller SE, Larsen F, Khan AZ, Rolan PE,. 2001. Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. J Clin Psychopharmacol 21: 493-499. (Pubitemid 32937432)
91. Monastero R, Camarda R, Camarda C,. 2007. Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease. Clin Ther 29: 2706-2709.
92. Mort JR, Aparasu RR, Baer RK,. 2006. Interaction between selective serotonin reuptake inhibitors and nonsteroidal anti-inflammatory drugs: review of the literature. Pharmacotherapy 26: 1307-1313. (Pubitemid 44306891)
93. Nagy CF, Kumar D G, Perdomo CA, et al,. 2004. Concurrent administration of donepezil HCl and sertraline in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol 58 (suppl 1): 25-33.
94. Nemeroff CB, Preskorn S, Devane CL,. 2007. Antidepressant drug-drug interactions: clinical relevance and risk management. CNS Spectr 12 (suppl 7): 1-13.
95. Olesen OV, Linnet K,. 2000. Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 20: 35-42. (Pubitemid 30056351)
96. Onalan O, Cumurcu BE, Bekar L,. 2008. Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Mayo Clin Proc 83: 595-599. (Pubitemid 351717009)
97. Opatrny L, Delaney JA, Suissa S,. 2008. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 66: 76-81. (Pubitemid 351822152)
98. Pae CU, Kim JJ, Lee CU, et al,. 2003. Provoked bradycardia after paroxetine administration. Gen Hosp Psychiatry 25: 142-144.
99. Pearson HJ,. 1990. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 51: 126. (Pubitemid 20107913)
100. Perucca E, Gatti G, Cipolla G, et al,. 1994. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 56: 471-476. (Pubitemid 24370353)
101. Preskorn SH, Alderman J, Chung M, et al,. 1994. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14: 90-98. (Pubitemid 24120706)
102. Preskorn SH, Greenblatt DJ, Flockhart D, et al,. 2007. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 27: 28-34. (Pubitemid 46105760)
103. Preskorn SH, Werder S,. 2006. Detrimental antidepressant drug-drug interactions: are they clinically relevant? Neuropsychopharmacology 31: 1605-1612. (Pubitemid 44106690)
104. Rapeport WG, Coates PE, Dewland PM, Forster PL,. 1996a. Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic changes. J Clin Psychiatry 57 (Suppl 1): 16-19. (Pubitemid 26143030)
105. Rapeport WG, Muirhead DC, Williams SA, et al,. 1996b. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 57 (suppl. 1): 24-28. (Pubitemid 26143031)
106. Rapeport WG, Williams SA, Muirhead DC, et al,. 1996c. Absence of sertraline-mediated effect of the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 57 (suppl. 1): 20-23. (Pubitemid 26144854)
107. Rendic S., 2002. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34: 83-448. (Pubitemid 34311090)
108. Repo-Tiihonen E, Eloranta A, Hallikainen T, Tiihonen J,. 2005. Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients. Neuropsychology 51: 173-176. (Pubitemid 40976398)
109. Saito M, Yasui-Furukori N, Nakagami T, et al,. 2005. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol 25: 527-532. (Pubitemid 41669043)
110. Samara EE, Granneman RG, Witt GF, Cavanaugh JH,. 1997. Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. J Clin Pharmacol 37: 442-450. (Pubitemid 27215072)
111. Santoro V, D'Arrigo C, Micò U, et al,. 2010. Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine and risperidone in patients with psychotic disorders. J Clin Psychopharmacol 30: 634-636.
112. Sayal KS, Duncan-McConnell DA, MCConnell HW, Taylor DM,. 2000. Psychotropic interactions with warfarin. Acta Psychiatr Scand 102: 250-252.
113. Scroth W, Goetz MP, Hamann U, et al,. 2009. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302: 1429-1436.
114. Shader RI, Greenblatt DJ, Von Moltke LL,. 1994. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 14: 375-376. (Pubitemid 24378137)
115. Spina E,. 2009. Drug interactions. In Treatment of Epilepsy, 3rd edn, Shorvon S, Perucca E, Engel J, (eds). Wiley-Blackwell Publishing Ltd.: Oxford; 361-377.
116. Spina E, Avenoso A, Facciolà G, et al,. 1998. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 13: 141-145. (Pubitemid 28318355)
117. Spina E, Avenoso A, Facciolà G, et al,. 2001. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 23: 223-227. (Pubitemid 32476548)
118. Spina E, Avenoso A, Pollicino AM, et al,. 1993. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 15: 247-250. (Pubitemid 23171911)
119. Spina E, Avenoso A, Salemi M, et al,. 2000. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 33: 213-217.
120. Spina E, Avenoso A, Scordo MG, et al,. 2002. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 22: 419-423. (Pubitemid 34810333)
121. Spina E, Campo GM, Avenoso A, Pollicino AM, Caputi AP,. 1992. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 14: 194-196.
122. Spina E, Perucca E,. 1994. Newer and older antidepressants. A comparative review of drug interactions. CNS Drugs 2: 479-497.
123. Spina E, Perucca E,. 2002. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 43 (suppl 2): 37-44. (Pubitemid 34229485)
124. Spina E, Santoro V, D'Arrigo C,. 2008. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30: 1206-1227.
125. Stearns V, Johnson MD, Rae JM, et al,. 2003. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758-1764. (Pubitemid 38008898)
126. Sternbach H,. 1991. Fluoxetine-associated potentiation of calcium channel blockers. J Clin Psychopharmacol 11: 390-391.
127. Suzuki Y, Shioiri T, Muratake T, et al,. 2003. Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles. Eur J Clin Pharmacol 58: 829-833. (Pubitemid 36577814)
128. Szegedi A, Anghelescu I, Wiesner J, et al,. 1999. Addition of low-dose of fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32: 148-153. (Pubitemid 29434281)
129. Tata LJ, Fortun PJ, Hubbard RB, et al,. 2005. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 22: 175-181. (Pubitemid 41153059)
130. Taylor D, Ellison Z, Ementon Shaw L, et al,. 1998. Co-administration of citalopram and clozapine: effect on plasma clozapine levels. Int Clin Psychopharmacol 13: 19-21. (Pubitemid 28092266)
131. US Food and Drug Administration. 2006. Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labelling. Draft Guidance. US Food and Drug Administration: Rockville, MD.
132. Van den Brekel AM,., Harringtol L,. 1994. Toxic effects of theophylline caused by fluvoxamine. Can Med Assoc J 151: 1289-1290.
133. Wallerstedt SM, Gleerup H, Sundstrom A, et al,. 2009. Risk of clinically relevant bleeding in warfarin-treated patients: influence of SSRI treatment. Pharmacoepidemiol Drug Saf 18: 412-416.
134. Walley T, Pirmohamed M, Proudlove C, Maxwell D,. 1993. Interaction of metoprolol and fluoxetine. Lancet 341: 967-968.
135. Weigmann H, Gerek S, Zeisig A, et al,. 2001. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 23: 410-413. (Pubitemid 32708927)
136. Weiss J, Dorman SM, Martin-Facklam M, et al,. 2003. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305: 197-204. (Pubitemid 36373851)
137. Westermeyer J,. 1991. Fluoxetine-induced tricyclic toxicity: extent and duration. J Clin Pharmacol 31: 388-392.
138. Wetzel H, Anghelescu I, Szegedi A, et al,. 1998. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 18: 2-9. (Pubitemid 28045628)
139. Woods DJ, Coulter DM, Pillans P,. 1994. Interaction of phenytoin and fluoxetine. New Zeal Med J 107: 19.
140. Woolfrey S, Gammack N, Dewar M, Brown P,. 1993. Fluoxetine-warfarin interaction. Br Med J 307: 241. (Pubitemid 23207906)
141. Yap KB, Low ST,. 1999. Interaction of fluvoxamine with warfarin in an elderly woman. Singapore Med J 40: 480-482. (Pubitemid 29376898)
142. Yasui-Furukori N, Kaneko S,. 2006. Digitalis intoxication induced by paroxetine co-administration. Lancet 367: 788. (Pubitemid 43326297)
143. Zhang L, Huang SM, Lesko LJ,. 2011. Transporter-mediated drug-drug interactions. Clin Pharmacol Ther 89: 481-484.